Back to search

Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy

NCT01061970

PHASE2INTERVENTIONAL
QuatRx Pharmaceuticals Company
15 participants
Started 2007-01 · Completed 2007-10
Status: Completed (as of 12-23-2025)

Conditions

HypogonadismChronic Obstructive Pulmonary Disease

Interventions

DRUG: Fispemifene

Linked Papers (from SciSciNet-V2)

Total Papers10
Background
0
Result
0
Derived
0
Unknown
10
View on ClinicalTrials.gov

Total Citations Per Year

Brief Summary

The objective of the study is to assess and compare the preliminary efficacy, safety and tolerability of fispemifene 300 mg and placebo given once daily for 4 weeks in the treatment of hypogonadal men with chronic obstructive pulmonary disease (COPD) that are on oral glucocorticoid therapy.

Sort by:

Background Papers0

No background papers linked

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers10

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2001
6,099 citations
Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial.
1995
467 citations
Effects of Testosterone and Resistance Training in Men with Chronic Obstructive Pulmonary Disease
2004
381 citations
Systemic Effects in COPD
2002
294 citations
The Influence of 6 Months of Oral Anabolic Steroids on Body Mass and Respiratory Muscles in Undernourished COPD Patients
1998
245 citations
Catabolic/Anabolic Balance and Muscle Wasting in Patients With COPD
2003
238 citations
Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy
1998
197 citations
Hypogonadism, Quadriceps Weakness, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease
2005
138 citations
Reversal of COPD-Associated Weight Loss Using the Anabolic Agent Oxandrolone
2002
132 citations
Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial
2004
109 citations